Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS 89 3-Year Revenue Growth Rate is 9.80% as of Jun. 2026, which is 1% below its 10-year median of 9.90. GuruFocus rates ASX:VLS with a GF Score™ of 89/100 and a GF Value™ of A$2.64 (Fairly Valued). The stock has 6 warning signs investors should review. Among 906 Drug Manufacturers companies, Vita Life Sciences ranks better than 71.41% on this metric.
During the past 12 months, Vita Life Sciences's average Revenue per Share Growth Rate was 11.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Vita Life Sciences was 19.10% per year. The lowest was -6.20% per year. And the median was 9.90% per year.
Vita Life Sciences (ASX:VLS) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Vita Life Sciences 3-Year Revenue Growth Rate Related Terms
ASX:VLS vs ZTS: 3-Year Revenue Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences 3-Year Revenue Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's 3-Year Revenue Growth Rate falls into.
Vita Life Sciences 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 9.80% mean?
Vita Life Sciences (ASX:VLS) has a 3-Year Revenue Growth Rate of 9.80% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Vita Life Sciences and its competitors. This is near median its historical median of 9.90. According to the industry distribution chart, Vita Life Sciences ranks #259 out of 906 companies in the Drug Manufacturers industry, placing it in the top 28.6%.
Is Vita Life Sciences' 3-Year Revenue Growth Rate too high?
Vita Life Sciences' current 3-Year Revenue Growth Rate of 9.80% is near median its 10-year median of 9.90. The Drug Manufacturers industry median 3-Year Revenue Growth Rate is 3.75. Vita Life Sciences' value of 9.80% is 161.3% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #259 out of 906 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' 3-Year Revenue Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #259 out of 906 companies for 3-Year Revenue Growth Rate. This puts Vita Life Sciences in the upper half of its industry. The industry median 3-Year Revenue Growth Rate is 3.75. Vita Life Sciences' value of 9.80% is 161.3% above this benchmark. While the company's 10-year median is 9.90 vs. the industry median of 3.75, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Drug Manufacturers company?
The median 3-Year Revenue Growth Rate among Drug Manufacturers companies is 3.75, based on 906 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current 3-Year Revenue Growth Rate of 9.80% is 161.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median 3-Year Revenue Growth Rate is 3.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current 3-Year Revenue Growth Rate is 9.80%, which is near median its own 10-year median of 9.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.64, compared to a current price of A$2.76 — trading 4.5% above its estimated fair value. The current 3-Year Revenue Growth Rate is 9.80%, which is near median its 10-year median of 9.90 and 161.3% above the Drug Manufacturers industry median of 3.75. Vita Life Sciences' overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current 3-Year Revenue Growth Rate is 9.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.76 is trading 4.5% above its estimated GF Value™ of A$2.64.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
3-Year Revenue Growth Rate: 9.80% (near median its 10-year median of 9.90)
GF Value™: A$2.64 vs. price of A$2.76 (4.5% above fair value)
Industry Position: 161.3% above the Drug Manufacturers median (#259 of 906)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
89GF Score
Get the complete analysis for ASX:VLS
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
